Investor Alert

press release

Jan. 5, 2021, 8:01 a.m. EST

Vir Biotechnology to Present at 39th Annual J.P. Morgan Healthcare Conference

SAN FRANCISCO, Jan 05, 2021 (GLOBE NEWSWIRE via COMTEX) -- SAN FRANCISCO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. /zigman2/quotes/214486077/composite VIR +2.98% , a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced that George Scangos, Ph.D., chief executive officer will virtually present at the 39 [th] Annual J.P. Morgan Healthcare Conference on Tuesday, January 12 [th] at 11:00 am PT/ 2:00 pm ET.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at www.vir.bio and will be archived there following the presentation for 30 days.

About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting SARS-CoV-2, hepatitis B virus, influenza A, human immunodeficiency virus and tuberculosis. For more information, please visit www.vir.bio .

        Vir Biotechnology, Inc.
        Neera Ravindran, MD
        VP, Head of Investor Relations & Strategic Communications
        Cara Miller
        VP, Corporate Communications


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2021 GlobeNewswire, Inc. All rights reserved.

US : U.S.: Nasdaq
$ 46.38
+1.34 +2.98%
Volume: 462,525
April 16, 2021 4:00p
P/E Ratio
Dividend Yield
Market Cap
$5.76 billion
Rev. per Employee

Partner Center

Link to MarketWatch's Slice.